Piper Sandler Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $68
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on ANI Pharmaceuticals with an Overweight rating and set a price target of $68.
October 11, 2024 | 9:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has initiated coverage on ANI Pharmaceuticals with an Overweight rating and a price target of $68, indicating a positive outlook.
The initiation of coverage with an Overweight rating and a specific price target of $68 by Piper Sandler suggests a positive outlook for ANI Pharmaceuticals. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100